The Use of Saliva as a Biological Fluid in Relative Bioavailability Studies: Comparison and Correlation with Plasma Results

被引:25
作者
Esperanza Ruiz, M.
Conforti, Paula
Fagiolino, Pietro [2 ]
Guillermina Volonte, M. [1 ]
机构
[1] Natl Univ La Plata, Fac Exact Sci, Dept Biol Sci, La Plata, Buenos Aires, Argentina
[2] Univ Republica, Fac Chem, Dept Pharmaceut Sci, Montevideo, Uruguay
关键词
saliva; in vitro-in vivo correlations; relative bioavailability; dissolution profiles; carbamazepine; CARBAMAZEPINE TABLETS; BIOEQUIVALENCE; DRUGS; IVIVC;
D O I
10.1002/bdd.728
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the present study was to present new evidence supporting the use of saliva as a biological fluid in relative bioavailability studies. Carbamazepine was chosen as a model drug because of its suitability for salivary therapeutic drug monitoring and its well-documented plasma bioavailability. A relative bioavailability study of four different immediate release carbamazepine products was performed. Stimulated saliva samples were collected by chewing on parafilm wax and by the spitting method. In vitro dissolution testing of formulations, using 900 ml of 1% sodium lauryl sulphate in water, was also carried out. The in vitro-in vivo correlations obtained in this salivary study were consistent with previous correlations assessed using plasma. These results support the suitability of saliva as the biological fluid in relative bioavailability studies. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:476 / 485
页数:10
相关论文
共 41 条
[1]  
ANDERSON GD, 2008, ADV STUD MED, V8, P229
[2]   Review: The physiology of saliva and transfer of drugs into saliva [J].
Aps, JKM ;
Martens, LC .
FORENSIC SCIENCE INTERNATIONAL, 2005, 150 (2-3) :119-131
[3]  
British Pharmacopoeia Commission, 2008, BRIT PHARM
[4]   FALLACIOUS RESULTS FROM MEASURING SALIVARY CARBAMAZEPINE CONCENTRATIONS [J].
DICKINSON, RG ;
HOOPER, WD ;
KING, AR ;
EADIE, MJ .
THERAPEUTIC DRUG MONITORING, 1985, 7 (01) :41-45
[5]   THERAPEUTIC DRUG-MONITORING IN SALIVA - AN UPDATE [J].
DROBITCH, RK ;
SVENSSON, CK .
CLINICAL PHARMACOKINETICS, 1992, 23 (05) :365-379
[6]  
Eadie MJ, 2001, BRIT J CLIN PHARMACO, V52, p11S
[7]  
[EMEA CPMP], 2001, NOT GUID INV BIOAV B
[8]  
Fagiolino P, 1999, MONITORIZACION FARMA
[9]  
FAIGLE JW, 1976, EPILEPTIC SEIZURES B, P127
[10]  
[FDA CDER], 2003, GUID IND BIOAV BIOEQ